Key Financial Figures - Q2 & H1FY27 Consolidated

Profit & Loss Statement (₹ in Crores):

  • Q2FY27 Revenue from Operations: ₹280 crs (vs ₹196 crs in Q2FY26, +43% YoY)
  • H1FY27 Revenue from Operations: ₹498 crs (vs ₹399 crs in H1FY26, +25% YoY)
  • Q2FY27 Gross Profit: ₹200 crs (Gross Margin: 71.6%, +750 bps YoY)
  • H1FY27 Gross Profit: ₹343 crs (Gross Margin: 68.8%, +580 bps YoY)
  • Q2FY27 Reported EBITDA: ₹92 crs (EBITDA Margin: 32.7%, +700 bps YoY)
  • H1FY27 Reported EBITDA: ₹136 crs (EBITDA Margin: 27.3%, +10 bps YoY)
  • Q2FY27 Profit After Tax: ₹52 crs (PAT Margin: 18.5%, +870 bps YoY)
  • H1FY27 Profit After Tax: ₹66 crs (PAT Margin: 13.2%, +90 bps YoY)
  • EBITDA includes one-time impact of ₹3 crs towards IPO listing expenses
  • New Businesses contributed operating expenses of ₹31 crs in Q2FY27 and ₹58 crs in H1FY27
  • New Businesses depreciation was ₹12 crs in Q2FY27 and ₹24 crs in H1FY27

Balance Sheet Position (as of September 30, 2026):

  • Total Assets: ₹2,044 crs (vs ₹1,781 crs as of March 31, 2026)
  • Property, Plant and Equipment: ₹1,055 crs
  • Capital Work-in-Progress: ₹138 crs
  • Inventories: ₹303 crs
  • Trade Receivables: ₹268 crs
  • Cash and Cash Equivalents: ₹22 crs
  • Total Equity: ₹1,361 crs
  • Borrowings: ₹333 crs (Non-current: ₹162 crs + Current: ₹171 crs)
  • Net Debt: Approximately ₹314 crs

Business Updates and Operational Highlights

API Business Performance:

  • API business delivered 11% YoY revenue growth in H1FY27
  • Successfully completed 4 major regulatory audits:
  • EUGMP audits at Rau and Pithampur plants in March 2026 - approval certification received
  • USFDA audits at Rau & Pithampur plants in H1FY27 - EIR received for both plants

Complex Injectables - DCV Products:

  • Signed licensing agreement for distribution of two DCV products in US
  • Completed milestones invoiced and part revenue of ₹53 crs recognized in Q2FY27
  • First molecule ANDA for DCV filed and accepted by USFDA successfully
  • Filing of second ANDA scheduled for Q4FY27 with PFC submitted qualifying for expedited Priority Review
  • Commercial supplies expected to commence next year

CDMO & Industrial Biotech Business:

  • 10-year take-or-pay agreement with US-based Alternate Protein player in place - project capex on track
  • 10-year take-or-pay term sheet with Europe-based Alternate Protein player - agreement signing in advanced stage
  • Initial manufacturing to commence in Q4FY27

Pharmaceutical - Insulin Drug Substance:

  • 5-year take-or-pay agreement in place, Capex on track
  • Filing regulatory approval in Q4FY27/Q1FY28

Capital Expenditure Details

Gross Capex Investment (as on September 30, 2026): ₹1,509 crs

Estimated Total Gross Capex (by end FY27): ₹1,672 crs

Capex Breakdown:

  • Existing Business (API - Steroids & Hormones): ₹649 crs (39% of total, currently generating revenue)
  • Complex Injectables - Dual Chamber Vials: ₹357 crs (est. ₹377 crs by FY27 end)
  • CDMO Services (400 kl + 14kl): ₹492 crs (est. ₹584 crs by FY27 end)
  • New API Capex: ₹12 crs (est. ₹63 crs by FY27 end)

Revenue Generation Timeline:

  • 39% of total gross capex currently generating revenue
  • 61% of gross capex in new projects yet to generate revenues
  • Approximately ₹1,000 crs (60% of capex) expected to start generating revenue in next 6-12 months

Management Commentary

Mr. Anil Satwani, Chairman & Managing Director, commented on strong Q2FY27 performance driven by core business progress and scaling of emerging growth engines. The company remains confident in growth outlook and believes Injectables and CDMO businesses have potential to scale meaningfully over coming years to reach size comparable to established API business.

Additional Information

  • Company Website: https://investor.symbiotec.com/financials?tab=presentations
  • Investor Relations Contact: Strategic Growth Advisors Pvt. Ltd.